Roche
RO.SW
#33
Rank
A$560.88 B
Marketcap
A$703.96
Share price
0.25%
Change (1 day)
31.47%
Change (1 year)

P/E ratio for Roche (RO.SW)

P/E ratio at the end of 2022: 19.2

According to Roche's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.7422. At the end of 2022 the company had a P/E ratio of 19.2.

P/E ratio history for Roche from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202219.2-18.23%
202123.529.87%
202018.1-15.58%
201921.4-0.99%
201821.6-17.87%
201726.312.51%
201623.4-19.56%
201529.17.95%
201427.044.51%
201318.711.26%
201216.811.32%
201115.17.43%
201014.0-37.01%
200922.323.37%
200818.0-16.64%
200721.6-32.25%
200632.0-22.32%
200541.194.98%
200421.1-54.94%
200346.8-336.57%
2002-19.8-174.53%
200126.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
41.3 74.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
31.0 30.41%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
38.7 62.88%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
40.6 71.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
28.4 19.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
24.7 4.12%๐Ÿ‡ซ๐Ÿ‡ท France
Becton Dickinson
BDX
58.9 147.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
148 522.55%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
17.5-26.33%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.